Acute Coronary Syndrome - Pipeline Review, H1 2015

Published: Jun, 2015 | Pages: 124 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Acute Coronary Syndrome - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Acute Coronary Syndrome - Pipeline Review, H1 2015', provides an overview of the Acute Coronary Syndrome's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Coronary Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Coronary Syndrome
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Acute Coronary Syndrome and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Acute Coronary Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acute Coronary Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acute Coronary Syndrome
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acute Coronary Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Acute Coronary Syndrome Overview 9
Therapeutics Development 10
Pipeline Products for Acute Coronary Syndrome - Overview 10
Pipeline Products for Acute Coronary Syndrome - Comparative Analysis 11
Acute Coronary Syndrome - Therapeutics under Development by Companies 12
Acute Coronary Syndrome - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Acute Coronary Syndrome - Products under Development by Companies 18
Acute Coronary Syndrome - Companies Involved in Therapeutics Development 20
advanceCor GmbH 20
Arena Pharmaceuticals, Inc. 21
Artery Therapeutics, Inc. 22
AstraZeneca PLC 23
Athera Biotechnologies AB 24
Auspex Pharmaceuticals, Inc. 25
Bayer AG 26
Esperion Therapeutics, Inc. 27
GlaxoSmithKline Plc 28
Lee's Pharmaceutical Holdings Limited 29
MedImmune, LLC 30
Pfizer Inc. 31
The Medicines Company 32
Vitae Pharmaceuticals, Inc. 33
XOMA Corporation 34
Acute Coronary Syndrome - Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Target 36
Assessment by Mechanism of Action 38
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
4-WF - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
AEM-28 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
AEM-28-02 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Artpep-2 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Biologics for Acute Coronary Syndrome - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
bivalirudin - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
cangrelor - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
COR-2 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
COR-3 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
gevokizumab - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
losmapimod - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
MDCO-216 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
MEDI-6012 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
MTP-131 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
PC-mAb - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
PF-06282999 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
PMC-6 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
PR-15 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
rivaroxaban - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
SD-970 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
temanogrel hydrochloride - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
VTP-38443 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
ZK-001 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Acute Coronary Syndrome - Recent Pipeline Updates 82
Acute Coronary Syndrome - Dormant Projects 108
Acute Coronary Syndrome - Discontinued Products 111
Acute Coronary Syndrome - Product Development Milestones 113
Featured News & Press Releases 113
May 11, 2015: Xarelto Bleeding Lawsuit Judge Orders the Selection of Cases for Discovery, Reports Xarelto Lawsuit Funding Firm, Fair Rate Funding 113
Mar 15, 2015: Stealth BioTherapeutics Announces EMBRACE Results: A Phase 2 Clinical Study of Bendavia in Acute Coronary Syndrome 113
Oct 22, 2014: NICE draft guidance recommends rivaroxaban (Xarelto) to prevent blood clots in people who have had a heart attack 114
Sep 02, 2014: Capstone Therapeutics Announces Phase 1a Results for AEM-28 Showing Safety and Biomarker Efficacy Signals 115
Aug 29, 2014: Janssen Expands EXPLORER Global Cardiovascular Research Program to Evaluate the Role of XARELTO in Addressing Critical Medical Needs 116
Jun 05, 2014: GSK announces start of phase III cardiovascular outcomes study with losmapimod in patients with acute coronary syndrome 118
Jan 16, 2014: FDA Advisory Committee Recommends Against Approval of the Use of Oral Anticoagulant XARELTO to Reduce the Risk of Thrombotic Cardiovascular Events in Patients with Acute Coronary Syndrome 118
Oct 07, 2013: Regulatory Update on Bayer's Xarelto (Rivaroxaban) 2.5 mg in ACS Indication 120
Sep 03, 2013: Totality of Data From Three Phase III Trials of The Medicines Company's Intravenous Cangrelor Presented and Published 120
Jun 28, 2013: FDA Issues Complete Response Letter for XARELTO to Reduce the Risk of Stent Thrombosis in Patients with Acute Coronary Syndrome 121
Appendix 123
Methodology 123
Coverage 123
Secondary Research 123
Primary Research 123
Expert Panel Validation 123
Contact Us 123
Disclaimer 124

List of Tables

Number of Products under Development for Acute Coronary Syndrome, H1 2015 10
Number of Products under Development for Acute Coronary Syndrome - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Development by Companies, H1 2015 (Contd..1) 14
Comparative Analysis by Late Stage Development, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Products under Development by Companies, H1 2015 18
Products under Development by Companies, H1 2015 (Contd..1) 19
Acute Coronary Syndrome - Pipeline by advanceCor GmbH, H1 2015 20
Acute Coronary Syndrome - Pipeline by Arena Pharmaceuticals, Inc., H1 2015 21
Acute Coronary Syndrome - Pipeline by Artery Therapeutics, Inc., H1 2015 22
Acute Coronary Syndrome - Pipeline by AstraZeneca PLC, H1 2015 23
Acute Coronary Syndrome - Pipeline by Athera Biotechnologies AB, H1 2015 24
Acute Coronary Syndrome - Pipeline by Auspex Pharmaceuticals, Inc., H1 2015 25
Acute Coronary Syndrome - Pipeline by Bayer AG, H1 2015 26
Acute Coronary Syndrome - Pipeline by Esperion Therapeutics, Inc., H1 2015 27
Acute Coronary Syndrome - Pipeline by GlaxoSmithKline Plc, H1 2015 28
Acute Coronary Syndrome - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2015 29
Acute Coronary Syndrome - Pipeline by MedImmune, LLC, H1 2015 30
Acute Coronary Syndrome - Pipeline by Pfizer Inc., H1 2015 31
Acute Coronary Syndrome - Pipeline by The Medicines Company, H1 2015 32
Acute Coronary Syndrome - Pipeline by Vitae Pharmaceuticals, Inc., H1 2015 33
Acute Coronary Syndrome - Pipeline by XOMA Corporation, H1 2015 34
Assessment by Monotherapy Products, H1 2015 35
Number of Products by Stage and Target, H1 2015 37
Number of Products by Stage and Mechanism of Action, H1 2015 39
Number of Products by Stage and Route of Administration, H1 2015 41
Number of Products by Stage and Molecule Type, H1 2015 43
Acute Coronary Syndrome Therapeutics - Recent Pipeline Updates, H1 2015 82
Acute Coronary Syndrome - Dormant Projects, H1 2015 108
Acute Coronary Syndrome - Dormant Projects (Contd..1), H1 2015 109
Acute Coronary Syndrome - Dormant Projects (Contd..2), H1 2015 110
Acute Coronary Syndrome - Discontinued Products, H1 2015 111
Acute Coronary Syndrome - Discontinued Products (Contd..1), H1 2015 112